Novartis Didn’t Build Seven Facilities to Make Drugs — It Built Them to Win a Tariff War
Novartis completes its $23B, seven-facility US manufacturing plan one year after launch — and the API strategy in North...
Pharma Reshoring
Novartis completes its $23B, seven-facility US manufacturing plan one year after launch — and the API strategy in North...